1Georgia Sotiropoulou, Georgios Pampalakis and Eleftherios P. Diamandis. Functional Roles of Human Kallikrein-related Peptidases. The Journal of Biological Chemistry, 2009,284(48):32989-32994.
2Claudio Ponticelli and Pier Luigi Meroni. Kallikreins and Lupus nephritis. The Journal of Clinical Investigation, 2009,119(4):768-771.
3Chao J, Zhang JJ, Lin KF, et al. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Human Gene Therapy, 1998, 9:21-31.
4Yayama K, Wang C, Chao L, et al. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats. ttypertension, 1998,31:1104-1110.
5Wang T, Li H, Zhao C, et al. Recombinat adeno-associated virus- mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Therapy, 2004, 11:1342-1350.
6Silva JA Jr, Araujo RC, Baltatu O, et al. Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J, 2000,14:1858-1860.
7Madeddu, P., et al. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation, 1997, 96:3570- 3578.
8Ritchie RH, Marsh JD. Lancaster WD, et al. Bradykinin blocks angiotensin ll-induced hypertrophy in the presence of endothelial cells. Hypertension, 1998, 31:39-44.
9Kim NN, Villegas S, Summerour SR,et al. Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J Mol Cell Cardiol, 1999,31:457-466.
10Hongun Yu, Qing Song, Barry I. Freedman, et al. Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney hlternational, 2002, 61 : 1030-1039.
